Lord, Abbett & Co. LLC Blueprint Medicines Corp Transaction History

Lord, Abbett & Co. LLC

$31.4 Billion
Q3 2024

A detailed history of Lord, Abbett & Co. LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 1,178,190 shares of BPMC stock, worth $107 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares

1,178,190

Previous 1,178,190 -0.0%

Holding current value

$107 Million

Previous $109 Million -0.0%

% of portfolio

0.35%

Previous 0.36%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$84.1 - $120.5 $1.01 Million - $1.44 Million	-11,960 Reduced 1.0%	1,178,190 $109 Million
Q2 2024 Oct 07, 2024	SELL	$85.18 - $108.78 $10.9 Million - $14 Million	-128,254 Reduced 9.73%	1,190,150 $128 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $10.9 Million - $14 Million	-128,254 Reduced 9.73%	1,190,150 $128 Million
Q1 2024 Oct 07, 2024	SELL	$73.17 - $99.79 $9.59 Million - $13.1 Million	-131,010 Reduced 9.04%	1,318,404 $125 Million
Q1 2024 May 09, 2024	SELL	$73.17 - $99.79 $9.59 Million - $13.1 Million	-131,010 Reduced 9.04%	1,318,404 $125 Million
Q4 2023 Oct 07, 2024	BUY	$43.96 - $92.84 $11.4 Million - $24.1 Million	259,264 Added 21.78%	1,449,414 $134 Million
Q4 2023 Feb 12, 2024	BUY	$43.96 - $92.84 $63.7 Million - $135 Million	1,449,414 New	1,449,414 $134 Million
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $30.4 Million - $61.9 Million	-562,489 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$94.25 - $115.99 $13 Million - $16 Million	137,882 Added 32.47%	562,489 $60.2 Million
Q3 2021 Nov 09, 2021	SELL	$80.98 - $109.47 $1.09 Million - $1.47 Million	-13,442 Reduced 3.07%	424,607 $43.7 Million
Q2 2021 Aug 11, 2021	SELL	$82.78 - $101.0 $3.71 Million - $4.52 Million	-44,797 Reduced 9.28%	438,049 $38.5 Million
Q1 2021 May 11, 2021	SELL	$90.71 - $108.28 $9.4 Million - $11.2 Million	-103,653 Reduced 17.67%	482,846 $46.9 Million
Q4 2020 Feb 09, 2021	BUY	$92.08 - $124.48 $15.6 Million - $21.1 Million	169,195 Added 40.54%	586,499 $65.8 Million
Q3 2020 Nov 12, 2020	BUY	$66.45 - $92.7 $7.09 Million - $9.89 Million	106,645 Added 34.33%	417,304 $38.7 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $770,144 - $1.07 Million	13,490 Added 4.54%	310,659 $24.2 Million
Q1 2020 May 14, 2020	SELL	$48.11 - $82.22 $11.2 Million - $19.2 Million	-233,007 Reduced 43.95%	297,169 $17.4 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $31.7 Million - $39.3 Million	-475,507 Reduced 47.28%	530,176 $42.5 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $2.14 Million - $2.97 Million	29,324 Added 3.0%	1,005,683 $73.9 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $10.7 Million - $14.2 Million	145,260 Added 17.48%	976,359 $92.1 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $14.4 Million - $25.6 Million	295,756 Added 55.25%	831,099 $66.5 Million
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $5.66 Million - $9.23 Million	124,282 Added 30.23%	535,343 $28.9 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $24.4 Million - $32.5 Million	-414,457 Reduced 50.21%	411,061 $32.1 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $46.8 Million - $77.7 Million	-767,561 Reduced 48.18%	825,518 $52.4 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $13.9 Million - $19.6 Million	-190,265 Reduced 10.67%	1,593,079 $146 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $1.13 Million - $1.59 Million	17,978 Added 1.02%	1,783,344 $134 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $1.53 Million - $2.52 Million	36,197 Added 2.09%	1,765,366 $123 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,729,169	1,729,169 $87.6 Million

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account

Lord, Abbett & Co. LLC Blueprint Medicines Corp Transaction History